Mark Sculpher

University of York — United Kingdom

Economics, Econometrics and Finance · Social Sciences

93h-index40.4kcitations644works21.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Health Systems, Economic Evaluations, Quality of Life(303), Healthcare cost, quality, practices(95), Healthcare Policy and Management(85), Pharmaceutical Economics and Policy(54), Global Health Care Issues(40)

Publications643 total

Reply to “On Selection and Analytical Transparency in the <scp>FRAME</scp> Framework for <scp>RWE</scp> Evaluation”
Clinical Pharmacology & Therapeutics·2026Open Access
Revised methods guide for economic evaluation studies of health technologies in Portugal
International Journal of Technology Assessment in Health Care·2026· 1 citedOpen Access
HPR19 Alternative Pricing Policies for Multi-Indication Products: A Quantitative Analysis
Value in Health·2025
CO26 Bayesian Dynamic Borrowing to Enhance Evidence for New Therapies
Value in Health·2025
HPR122 Including Decision Uncertainty About the Clinically Minimal Important Difference: Shifting From Risk Aversion to Risk Awareness in Drug Reimbursement Processes
Value in Health·2025
P8 Assessing the Full Life-Cycle Value of Highly Specialized Technologies and Advanced Therapy Medicinal Products in England
Value in Health·2025
Correction: A Framework for Using Cost‑effectiveness Analysis to Support Pricing and Reimbursement Decisions for New Pharmaceuticals in a Context of Evolving Treatments, Prices, and Evidence
PharmacoEconomics·2025Open Access
<scp>FRAME</scp>: Framework for Real‐World Evidence Assessment to Mitigate Evidence Uncertainties for Efficacy/Effectiveness – An Evaluation of Regulatory and Health Technology Assessment Decision Making
Clinical Pharmacology & Therapeutics·2025· 2 citedOpen Access
Correction: Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime-Avibactam to Inform Delinked Payments by the NHS in England
Applied Health Economics and Health Policy·2025Open Access
Guiding Health Resource Allocation: Using Population Net Health Benefit to Align Disease Burden with Cost Effectiveness for Informed Decision Making
Applied Health Economics and Health Policy·2025· 1 citedOpen Access
Development of the natural history component of an early economic model for primary sclerosing cholangitis
Orphanet Journal of Rare Diseases·2025· 1 citedOpen Access
A0075 – IP9 – ATLAS (Approaches To Long-term Active Surveillance): A randomised controlled trial of regular MRI scans versus standard care in patients with low to intermediate risk prostate cancer on active surveillance
European Urology·2025Open Access
Cost-Effectiveness of Introducing Nuvaxovid to COVID-19 Vaccination in the United Kingdom: A Dynamic Transmission Model
Vaccines·2025Open Access
Health-related quality of life implications of plantar ulcers resulting from neuropathic damage caused by leprosy: An analysis from the trial of autologous blood products (TABLE trial) in Nepal
PLoS ONE·2025Open Access
A Framework for Using Cost-effectiveness Analysis to Support Pricing and Reimbursement Decisions for New Pharmaceuticals in a Context of Evolving Treatments, Prices, and Evidence
PharmacoEconomics·2024· 2 citedOpen Access
EE106 Cost-Effectiveness of Introducing Nuvaxovid to COVID-19 Vaccination in the United Kingdom: A Dynamic Transmission Model
Value in Health·2024· 1 citedOpen Access
Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime-Avibactam to Inform Delinked Payments by the NHS in England
Applied Health Economics and Health Policy·2024· 2 citedOpen Access
Cost-Effectiveness of Introducing Nuvaxovid to COVID-19 Vaccination in the United Kingdom: Dynamic Transmission Model
Preprints.org·2024Open Access
Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model
Health Technology Assessment·2024· 2 citedOpen Access
Using economic analysis to inform health resource allocation: lessons from Malawi
Discover Health Systems·2024· 1 citedOpen Access
page 1 of 33Next →

Frequent Co-authors

Karl Claxton(17), Andrew Briggs(9), Martin Buxton(6), Andrea Manca(5), Elisabeth Fenwick(4), Su Golder(4), Michael Drummond(4), Michael Drummond(4), Janet T. Powell(4), Neil Hawkins(3), Laura Bojke(3), Chris McCabe(3), R M Greenhalgh(3), David Epstein(3), Helen Weatherly(3), Catriona McDaid(3), Paul Revill(2), Milton C. Weinstein(2), Jonathan Karnon(2), A. David Paltiel(2)